Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02017444

Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. — IIH:DT  

Idiopathic Intracranial Hypertension Clinical Trial

Official title:
Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.

Clinical Trial Summary

Assessing the safety and effectiveness of a 11-βhydroxysteroid dehydrogenase type 1 inhibitor (AZD4017), in a placebo controlled trial, in acute idiopathic intracranial hypertension (IIH) IIH is a condition of young, overweight women with characteristic raised intracranial pressure (pressure around the brain) leading to papilloedema (swelling of the nerve supplying the eye), visual loss and headaches. Medical literature (Cochrane review) demonstrates there is little evidence for the treatments used for IIH. Weight control appears the most effective method of improving symptoms but weight loss is difficult to maintain. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme which regulates local steroid levels and our previous research suggests it may influence the production of brain fluid(cerebrospinal fluid or CSF). 11β-HSD1 levels fall with weight loss and this is associated with with decreased intracranial pressure. Our primary outcome is to determine whether AZD4017, an inhibitor of 11β-HSD1, will reduce the pressure in the brain and as a consequence improve IIH. Patients are eligible to enter the study if they are between 18-55 years old with acute (<6 months) IIH, signs of active disease (papilloedema and raised CSF pressure (>25 cmH20)), no other major illnesses and have no plans for pregnancy during the study period. This is an MRC funded single centre, phase II, double-blinded, randomised control drug trial. It will be conducted at the University Hospital Birmingham and the University of Birmingham will act as Sponsor. Eligible participants will be randomly assigned to AZD4017 or a placebo ('dummy' with no active drug) for 3 months with a follow up a month later. Investigations during the study will include bloods, urine samples, pregnancy tests, lumbar punctures, DXA scans and small fat/skin biopsies. Participants will benefit from increased monitoring and a potential improvement in their condition. We hypothesise that specific inhibition of 11β-HSD1 will decrease intracranial pressure and consequently treat patients with IIH, thus opening a new and entirely novel therapeutic avenue.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02017444
Study type Interventional
Source University of Birmingham
Contact
Status Completed
Phase Phase 2
Start date April 25, 2014
Completion date December 19, 2016
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01863381 - Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement N/A
Recruiting NCT06027567 - The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure Phase 4
Active, not recruiting NCT02896452 - Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome
Recruiting NCT06059703 - Biomarkers in the Etiology of Idiopathic Intracranial Hypertension N/A
Terminated NCT05347147 - A Trial to Determine the Efficacy and Safety of Presendin in IIH Phase 3
Not yet recruiting NCT06361823 - Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment Phase 3
Active, not recruiting NCT02124486 - An RCT of Bariatric Surgery vs a Community Weight Loss Programme for the Sustained Treatment of IIH N/A
Recruiting NCT02143258 - Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension N/A
Enrolling by invitation NCT05308823 - Outcome of Cerebral Venous Sinuses Stenting on Idiopathic Intracranial Hypertension N/A
Not yet recruiting NCT05762367 - MR Lymphatic Imaging in Idiopathic Intracranial Hypertention N/A
Not yet recruiting NCT06436820 - ICP & Outflow Study
Completed NCT03867461 - The Effects of MAP and EtCO2 on Venous Sinus Pressures N/A
Completed NCT03963336 - Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension Early Phase 1
Completed NCT01003639 - Idiopathic Intracranial Hypertension Treatment Trial Phase 2/Phase 3
Recruiting NCT03096743 - Evaluating Raised Intracranial Pressure Using MR Elastography N/A
Completed NCT04314128 - Assessment of ICP in Idiopathic Intracranial Hypertension Using Transocular Ultrasound and Transcranial Doppler N/A
Terminated NCT03501966 - Surgical Idiopathic Intracranial Hypertension Treatment Trial Phase 3
Active, not recruiting NCT03556085 - Venous Sinus Stenting With the River Stent in IIH N/A